Arvinas Inc Dossier
Qualitative Analysis
Business overview
Arvinas, Inc. is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD). Founded in 2013 by Professor Craig Crews of Yale University, the company utilizes its proprietary PROTAC (PROteolysis TArgeting Chimera) Discovery Engine platform to engineer therapies that hijack the body's natural ubiquitin-proteasome system to selectively degrade and remove disease-causing proteins. This innovative approach targets proteins that have historically been considered "undruggable" by conventional small-molecule inhibitors. Arvinas' clinical and preclinical pipeline spans oncology and neuroscience, with lead programs targeting estrogen receptors in breast cancer and androgen receptors in prostate cancer.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Streamlining operations and focusing resources on high-potential clinical programs (ARV-102, ARV-393, ARV-027, and ARV-6723) while implementing cost-efficiency measures and workforce reductions to extend the cash runway.
Expected impact: Extends the company's financial runway into the second half of 2028, allowing it to reach key clinical data readouts without near-term equity dilution.
Completing the Phase 1 monotherapy dose escalation trial of ARV-806 (targeting KRAS G12D) and seeking an out-licensing partner for any further clinical development (such as dose expansion or combination trials) rather than advancing it alone.
Expected impact: Mitigates late-stage clinical development risk and preserves capital while maintaining upside optionality through licensing economics.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Transfers exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant), the first FDA-approved PROTAC, to a partner with an established oncology commercial infrastructure.
Terms: $70 million upfront payment (shared 50/50 with Pfizer, resulting in $35 million to Arvinas), $15 million transition payment, up to $320 million in future development, regulatory, and commercial milestones, plus tiered royalties in the mid-teens to mid-20s on net sales.
Joint development of vepdegestrant (VEPPANU). Although commercialization rights have been licensed to Rigel, Arvinas and Pfizer continue to share ongoing development activities and split all licensing economics 50/50.
Terms: 50/50 split of all development costs, commercialization expenses, and licensing revenues (including upfront, milestone, and royalty payments from Rigel).